Form 4: Justin Gover Receives Equity Grant at COMPASS Pathways

Director Justin Gover was granted 21,110 share options in COMPASS Pathways plc as part of a standard equity compensation arrangement.

Summary

• Director Justin Gover received a grant of 21,110 share options on May 27, 2026.
• The options have an exercise price of $11.85 per share.
• The options are set to expire on May 26, 2036.
• Vesting occurs on the earlier of the first anniversary of the grant or the 2027 Annual General Meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying shares relative to the $11.85 exercise price.

Future Outlook

The filing does not provide forward-looking business guidance, as it is a disclosure of director compensation.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure leadership retention and alignment with corporate milestones.

Comparison to Industry Standards

• The grant structure follows standard industry practices for non-executive director compensation in clinical-stage biotech firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of May 27, 2027, or the 2027 Annual General Meeting.

Key Dates

Keywords

COMPASS Pathways, CMPS, Insider Trading, Form 4, Equity Compensation, Biotech